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A  ~ cross-sectional area 
Ai  ~ initial drug concentration 
Ai  ~ relative intensities  
ATR-FTIR ~ Attenuated total reflectance Fourier transform infrared spectroscopy 
AUC    ~ area under curve 
CS  ~ saturation solubility 
CNS  ~ central nervous system 
D  ~ diffusion coefficient 
Da   ~ Dalton 
dC  ~ concentration gradient 
dt  ~ time of diffusion 
dx  ~ thickness of a layer 
dw  ~ quantity of the dissolved substance 
F  ~ fraction released from matrix devices 
FT-IR   ~ Fourier transform infrared spectroscopy 
G    ~ rotation speed 
h   ~ hour 
h( )  ~ lifetime distribution function 
iv  ~ intravenous 
JPE  ~ Japanese Pharmaceutical Excipients 
k   ~ rate constant of the drug release 
L  ~ thickness of matrix film 
Mt   ~ amount of the drug released at time t  
M∞   ~ total amount of the released drug at infinite time 
n   ~ number of samples 
o-Ps     ~ ortho-positronium atom 
PALS   ~ positron annihilation lifetime spectroscopy  
PSA  ~ pressure sensitive adhesives  
Ph. Eur. ~ European Pharmacopoeia 
Ps  ~ positronium  
R   ~ radius of the free volume hole 
R
2
  ~ correlation coefficient 
RSD  ~ relative standard deviation 
S(t)  ~ lifetime spectrum  
t0  ~ lag-time (min) of the dissolution 
TTS  ~ transdermal therapeutic system 
USP/NF ~ United States Pharmacopeia – National Formulary 
% w/w  ~ percentage weight in weight 
I  ~ separate lifetimes  
β  ~ shape parameter of the curve 
R   ~ constant for the positronium lifetime 
ε  ~ porosity 
Τ  ~ tortuosity 





   ~ positronium lifetime  
2  ~ medium long lifetime  







Transdermal therapeutic systems (TTSs) allow delivery of contained drug into the 
systemic circulation via permeation through skin layers at a controlled rate. These 
systems are easy to apply and remove as and when desired. This approach of drug 
delivery is more pertinent in case of chronic disorders, such as hypertension, which 
require long-term dosing to maintain therapeutic drug concentration. Transdermal 
delivery of cardiovascular drugs offers several advantages, and transdermal forms of 
nitroglycerin and clonidine have been marketed. Transdermal delivery of one of the 
common class of cardiovascular drugs, – blockers –, has also been investigated and can 
offer benefits. Metoprolol tartrate is a selective hydrophilic ß-blocking agent for the 
treatment of mild and moderate hypertension and also for long term management of 
angina pectoris. Metoprolol tartrate with hydrophilic character is 95% absorbed and has 
a bioavailability of 40- to 50% in oral dosage forms. Peak plasma concentrations are 
achieved after 2–3 hours, and half life of the molecule is 3 to 7 hours. This makes 
frequent dosing necessary to maintain the therapeutic blood levels of the drug for long-
term treatment. The n-octanol/water partition coefficient is 0.98 at pH 7.4. Therefore, 
metoprolol is an ideal drug candidate for transdermal drug delivery, which makes a 
once-a-day dose treatment possible, thus improving the patient compliance. 
Matrix type TTS could be an appropriate vehicle for sustain-release of metoprolol 
tartrate. The application of different polymer matrices enables the control of the rate and 
the amount of the released drug. Acrylic polymers (Eudragit) and cellulose ether 
polymers (Metolose) are often used in pharmaceutical preparations with different 
purposes, such as binding-, coating- and sealing tablets, and also for retarding the drug 
release from tablets. Acrylic polymers have good skin compatibility, and are able to 
form films. Metolose polymers can also be characterized with good skin compatibility 
and film forming ability. Applying the casting method they can be ideally combined 
with each other for film forming. Choose of different types of these excipients enables 
the influence of the drug release rate- and amount from the vehicles containing 
metoprolol tartrate. 
In order to reveal information about the structure of polymer films containing drugs are 





atomic force microscopy makes possible to get much more detailed information about 
their 3D surface properties. A new promising method for the analysis of polymer films 
is the application of positron annihilation lifetime spectroscopy (PALS), which gives 
valuable data about the supramolecular characteristics of patches with the determination 

































3.1. THERAPEUTIC SYSTEMS 
 
The classical dosage forms are usually 2 dimensional including dose in volume. The 
next generations of drug products are 3 dimensional forms, where the third dimension is 
time. 
The 3 dimensional preparations include: 
 
- prolonged action preparations 
- controlled release dosage forms 
- targeted delivery systems 
- pulsatile release.  
 
Among these categories the controlled release dosage forms contain the therapeutic 
systems. The most popular representatives of this class are the transdermal therapeutic 
systems (TTS). 
The applied drug can be given by the use of therapeutic systems during a predetermined 
time with steady-state delivery rate. These systems do not always contain the usual  
(oral) dosage, which can lower the onset of side-effects. They are also able to sustain 
constant therapeutic steady-state blood level, because the eliminated drug is supplied by 
these systems to the body and / or to the determined organ.  
With the recognition of the advantages of these systems, they are widely used in 
therapies of several diseases. 
 
They can be categorized as follows [1]: 
 
I. Therapeutic systems with systemic effect 
- parenteral systems 
- transdermal therapeutic systems 
- oral therapeutic systems 





- pulsating therapeutic system 
- rectal therapeutic systems 
 
II.  Therapeutic systems with local effect 
- therapeutic systems for intrauterine application 




3.2. TRANSDERMAL THERAPEUTIC SYSTEMS 
 
The drug content of transdermal therapeutic systems (TTS) is able to penetrate through 
the different layers of the skin to reach the systemic circulation and / or the organ, where 
the drug is ready to give its therapeutic effect. 
There are many advantages of these systems [2-5]: 
 
- the drug avoids the liver, which results in delayed metabolization of the drug 
- it does not oppress the liver and the GI tract 
- it enhances the biological half time of the drug (through avoiding the liver) 
- it results in higher bioavailability of the drug 
- toxicity and side effects are lowered 
- it enables an application form without pain  
- they ensure precise dosage 
- smaller doses can also give the same therapeutic effect 
- there can be also drugs applied, which could be used only via iv. injection or 
infusion because of the metabolization 
- they lower the risk of microbiological contamination 
- the effect of food and drinks does not affect the liberation of the drug 
- drugs with short biological half time can be also applied  
- enhance the patient compliance 






Most of the dermal preparations are creams and ointments, which do not enable precise 
dosage of the drug, because the thickness of the applied preparation cannot be exactly 
determined, and it is fast unavoidable to wash off some part of the system [6]. To reach 
the required local therapeutic effect they need to be applied not only once a day. 
These clinical facts lead to the development of the transdermal therapeutic systems 
(TTS), which are able to ensure systemic effect with predetermined time with steady-
state delivery rate.  
There are also disadvantages of TTS [7-10]: 
 
- at the first time of application, a certain time is needed to reach the therapeutic 
blood level  
- drugs, the application of which leaded to skin irritation are not applicable in 
TTS 
- chemical modifiers in patches can also lead to skin irritation 
- extended application at the same surface of the skin can cause allergy symptoms 
- a limited range of drugs can be applied in TTS because of the slight penetration 




3.3. SKIN AS A BARRIER AND TRANSFER TO SYSTEMIC 
BLOOD CIRCULATION 
 
Skin, as the biggest organ, plays a very important role in the protection of the body 




The main barriers to transdermal delivery are the stratum corneum and the stratum 
lucidum in the epidermis layer, respectively. The stratum corneum is a horny layer of 
the skin; the thickness of this layer is between 10 -15 µm and consists of 10-25 layers. It 





proteins [11, 12]. There can be found intercellular lamellar lipids between these thin 
layers. They are residue of the membrane surrounding each epidermal cell and they 
come into existence when the epidermal cells are embodied. This lipid contains 
ceramides, free sterols, free acids, sterol esters, triglycerides, etc. These lipids are able 
to organize themselves into membrane bilayers, although they do not contain any 
phospholipids [13]. All the components of the interstitial lipids contribute to the barrier 






Figure 1 – The different layers of the skin [14]  
 
 
The transepidermal delivery of the drugs has three major pathways in the stratum 
corneum [15, 16] 







The paracellular pathway involves the lamellar lipids into the transport of drugs, which 
are essentially responsible for the sticking of the epidermal cells. During the 
transcellular transportation the drugs pass through the cells of the stratum corneum. 
Most of the substances diffuse through this layer via the paracellular lipoidal pathway 
[17]. Nonetheless, paracellular and transcellular routes can play a role in combination 
during the transportation of drugs. The appendage route composed of hair follicles, 
sebaceous glands and sweat glands is considered to be substantially less important for 
drug transport, as this route accounts for less than 0.1 percent of the total surface area of 
the skin. This route may be of some importance for large ionic molecules. Drugs which 
diffuse through the sebaceous glands come first into the dermis and then into the 
subcutis [18, 19]. Figure 2 shows the routes of transdermal delivery. 
 
 
Figure 2 – Delivery pathways of transdermal delivery 
 
 
The other important barrier for many drugs is the stratum lucidum, which consist of 1 or 
2 cell lines. It is an electronegative barrier and the electronegative drugs are not able to 
cross the stratum lucidum because of this negative shift. The positively charged drugs 
are pulled by this layer. Iontophoretic treatment can extinguish the effect of this barrier 





At the surface of the skin there can be found an acid protecting layer, through which all 




3.4. PHYSICOCHEMICAL PROPERTIES OF DRUGS WITH 
SKIN PERMEATION  
 
The lipids in the epidermis play a very important role in the penetration of drugs into 
the skin. The protein parts of the epidermis can bind water and they become hydrated. 
This hydrated state helps also in the better penetration of drugs. With this hydration the 
dermis behaves as a protein gel regarding the penetration of the drugs. Whether the drug 
can penetrate into the skin and reach the systemic blood circulation and / or the specific 
organ depends also on the structure of the drug. Most drugs are not suitable for 
transdermal delivery for one or more reasons. The desirable physicochemical, 
pharmacokinetic and biopharmaceutical characteristics of a candidate drug are: 
 
- low daily dose (less than 20 mg/day) 
- short half-life (10 hours or less) 
- low molecular weight (less than 400 Da) 
- low melting point (less than 200°C) 
- high lipid solubility (octanol/water partition coefficient – /logP/ between -1.0 
and 4)  
- high skin permeability (permeability coefficient greater than 0.5 x 10-3 cm/h) 
- non-irritating and non-sensitizing to skin. 
 
Low oral bioavailability and low therapeutic index, which requires tight control of 
plasma levels, are not required characteristics of drugs for transdermal delivery, but they 
confirm the application of a candidate drug in TTS [23- 28].  
Generally only a few of the candidates could fulfill all these requirements: the high oral 





the transdermal application. An acceptable balance between these requirements must be 
established for the drug delivery in TTS.   
Drugs can have high skin permeability with the following characteristics: 
 
- high dipole moments 
- able to form hydrogen binding 
- are amphiphilic 
- have low molecular weight. 
 
If the drugs are applied on the skin they can  
 
- treat local diseases or 
- they can form reservoirs glued to the cells of the stratum corneum or of the 
dermis or 
- they can penetrate into the deeper regions of the skin or 
- they are metabolized by the enzymes of the skin or 




3.5. ENHANCING THE PERMEATION INTO THE SKIN 
 
Transdermal systems are applied in not such a wide range in the practice because of the 
poor permeation of the drugs into the skin. There are several possibilities to improve the 




- scraping of the stratum corneum 
- hydration of the stratum corneum [29, 30] 






- application of ultrasound energy on the skin  




- synthesis of lipophilic drugs  
- delipidation of the stratum corneum 




- synthesis of prodrugs which are able for bioconversion in the skin [35, 36] 
- application of enhancers can reduce the residence time in the skin, and thus 








Iontophoresis involves application of a low intensity electric current to facilitate the 
permeation of a drug into the skin. Iontophoresis can increase the rate of transdermal 
penetration of hydrophilic compounds [37, 38].  
Peptides could not be applied in TTS because of their high molecular weight, instability, 
low biological half-life and mainly polar characteristics [39]. The application of 












Electroporation is a method of application of short, high voltage electrical pulses to the 
skin. These electrical pulses form transient aqueous pores in the stratum corneum 
through which the drug molecules pass with electrophorese and / or electroosmose. This 
method allows a much more effective diffusion of drugs, respectively in the case of 
proteins [41-43]. The disadvantage of this system is the nerve irritation caused by the 
application of electrical pulses. The application of 2 phase continuous current can 
minimize the irritation and the lesion of the nerve endings. Electroporation can be 
achieved also with patches of which structure is much more difficult and therefore the 




Phonophoresis (or sonophoresis) uses ultrasound energy in order to enhance the skin 
penetration of active substances [44-46]. When skin is exposed to ultrasound, the waves 
propagate to a certain level and cause several effects that assist skin penetration. One of 
these effects is the cavitation, which means formation and subsequent collapse of gas 
bubbles in a liquid. This cavitation leads to formation of holes in the corneocytes, 
enlargement of intercellular spaces, and perturbation of stratum corneum lipids. Another 
effect is the heating of skin due to the energy loss of the propagating ultrasound wave 
(scattering and absorption effects). The resulting temperature elevation will increase the 
fluidity of the stratum corneum lipids and increase the diffusivity of molecules through 
the skin barrier. These main effects can be assisted by acoustic microstreaming caused 
by the acoustic shear stress which is due to unequal distribution of pressure forces. 
 
3.5.1.4. Thermoresponsive systems 
 
A new direction for pharmaceutical and medical research have been made with 
formulations based on stimuli-responsive polymers, because temporal drug release may 
be required, when the severity of disease symptoms fluctuate with time. If 





of temperature, thermoresponsive polymers may be used to develop hydrogels which 
react with their physical characteristics on the changes of their environment [47-49]. 
Thermoresponsive transdermal therapeutic systems consist of thermoresponsive agents 
(polymer, liquid crystals, liposomes), which suffer phase transition according to the 
change of temperature regulating drug delivery. This phase transition may be soluble-
insoluble state variation, sol-gel transition, liquid crystal phase transitions, crystalline-




3.5.2.  Application of prodrugs 
 
Prodrugs are inactive forms of drugs, which are transferred in the body with hydrolytic- 
and enzymatic bioconversion into the active forms of drugs. The application of prodrugs 
has an important role in the case of drugs, which could not penetrate in the original form 
into the skin [53, 54].  
At the application of TTS the drugs pass the different layers of the skin, where they can 
be modified by the metabolic enzymes (such as o-methyltransferase, aryl-hydrocarbon-
hydrolase) [55]. The inactive prodrugs are metabolized with these enzymes into the 
active drugs. This bioconversion can be applied for example in the case of the less 
permeable estrogen. These esterificated estrogens (estradiol acetate, estradiol diacetate, 
estradiol valerate) can penetrate into the skin much more intensively and they are fast 




3.5.3.  Application of enhancers 
 
Increasing drug penetration through the skin needs penetration enhancers which modify 
the lipid organization in the stratum corneum. Depending on their molecular structure 
they can act in the following ways: 





- disturbing of the lamellar packing 
- forming separate small domains in the lateral packing in the lamellae 
- forming enhancer-rich large separate domains in the intercellular regions [59, 
60]. 
 
The structure of skin is modified as a result at the application of enhancers: 
  
- they can change the hydration of the skin thanks to their higher water content in 
comparison with the skin. In this case the evaporation of the water in the TTS 
can lead to the hydration of the skin.  
- lipophilic enhancers form a thin layer on the surface of the skin and lower the 
evaporation of the endogenous water from the skin (W/O emulsions) [61]. 
 
The transepidermal transportation of drugs can be positively affected by the hydration 
of the different layers of the skin. The transfollicular pathway can lead to a problem that 
the drug and the enhancer can be separated from each other in the sebaceous glands. 
The keratolytic agents can loosen up the structure of the stratum corneum.  
The surface active ingredients can solubilize the fat layer, which can quicken the 
transport during the lipid layer. These enhancers can be saturated and unsaturated fatty 
acids, from which the dodecyl chain length or the unsaturated C18 chain length is the 
most favorable for increasing drug transport across the skin [62, 63]. The fatty acids are 
applied with hydrocortisone or indomethacin [64, 65].  
There are also other enhancers such as dimethyl sulfoxide [66, 67].  
There is no general preference for any particular penetration enhancer or family of 
enhancers, because their effect depends on the interactions with the applied drug. The 
different types of enhancers can be varied with each other to goal a better absorption 










3.6. CLASSIFICATION OF TTS 
 
In the general characterization of TTS are the following components: 
 
- backing films 
- drug reservoir 
- rate-controlling membrane 
- pressure sensitive adhesives (PSA) 
- protective pressure sensitive adhesive release liner. 
 
In many cases one component can fulfill the role of the other components. 
The TTSs can be classified on the base of the drug-release mechanism: 
 
- membrane permeation controlled patch 
- adhesive dispersion controlled patch 
- matrix diffusion controlled patch 
- microreservoir controlled patch. 
 
The TTSs are characterized by steady-state delivery rate, the whole dose and the 




3.6.1.  Membrane permeation controlled TTS 
 
The release-rate from the reservoir is controlled by a membrane which is permeable for 
the drug. This membrane can be porous or not porous polymer membrane. The outer 
surface of the membrane is thin, compatible with the drug and hypoallergenic. The 
pressure sensitive adhesive ensures the cohesion between the skin and the TTS (Figure 





reservoir, by the composition of the rate-controlling membrane and by the thickness, the 
structure and the permeability coefficient of the adhesive.  
 
1. impermeable backing liner; 2. drug reservoir; 3. rate-controlling membrane;  
4. pressure sensitive adhesive; 5. release liner 
 
Figure 3 – Structure of membrane permeation controlled patch 
 
The main advantage of this TTS is the nearly constant drug release-rate and the 





3.6.2.  Adhesive dispersion controlled TTS 
 
In this simplified membrane permeation controlled patch the drug enhancer adhesive 
matrix polymer contains the drug (it is dispersed in polyisobutylene, polyacrylate 
polymers). This polymer matrix is clamped to the impermeable backing liner in one or 
more layers [71, 72]. The disadvantage of this type of TTS is that the drug release-rate 
is getting smaller during the time of application because of the expansion of the 
polymer layer (the drug needs to diffuse through this layer). This release-rate can be 
enhanced with the application of more polymer layers, which have more drug content 









    
 
 
1. impermeable backing layer; 2. drug in adhesive; 3. release liner 
 




3.6.3. Matrix diffusion controlled TTS 
 
The matrix diffusion controlled patches (Figure 5) have more simple structure in 
comparison with the other type of TTS’s: they do not contain any rate-controlling 






1. impermeable backing layer; 2. absorbent pad; 3. occlusive baseplate; 
4. drug reservoir; 5. adhesive; 6. release liner 
 
Figure 5 – Matrix diffusion controlled patch 
 
Drug reservoir is prepared by dissolving the drug and polymer in a common water-





lipophilic polymer. The required quantity of plasticizer (triethylcitrate, polyethylene 
glycol, propylene glycol and permeation enhancer) is then added and mixed properly. 
The medicated polymer is then moulded into rings with defined surface area and 
controlled thickness over the teflon cover on horizontal surface followed by solvent 
evaporation at an elevated temperature. The formed film is then separated from the 
rings, which is then mounted onto an occlusive base plate in a compartment fabricated 
from a drug impermeable backing. Adhesive polymer is then spread along the 
circumference of the film
 
[76]. Commonly used polymers for matrix are cross linked 
polyethylene glycol, polyacrylates, ethylcellulose, polyvinylpyrrolidone and 
hydroxypropyl methylcellulose. In an ideal case, the swelling of the polymer, which 
contains the drug, can be influenced that way, that the fluxation of water into the 
polymer and the diffusion of the drug occur at steady-state rate. Advantages of matrix 
patches include absence of dose dumping, direct exposure of polymeric matrix to the 




3.6.4.  Microreservoir controlled TTS 
 
The drug is suspended in an aqueous solution of water miscible drug solubilizer e.g. 
polyethylene glycol. The drug suspension is homogenously dispersed by a high shear 
mechanical force in lipophilic polymer, forming thousands of microscopic drug 
reservoirs (10-200 μm). The dispersion is quickly stabilized by cross-linking the 
polymer chains in-situ, which produces a medicated polymer disc of a specific area and 
fixed thickness. Occlusive base plate mounted between the medicated disc and adhesive 
form backing prevent the loss of drug through the backing membrane [77]. This system 
is exemplified by development of Nitrodisc
®
. Figure 6 presents the structure of 











3.7. KINETIC CONSIDERATION OF TTS  
 
Based on observations of experimental data, it may be stated that the differences in the 
therapeutic effect of different drug products (which contain the same drug constituents) 
are most frequently caused by differences in the rates at which the active ingredients are 
liberated from the given dosage form [78]. 
The process of diffusion has been described quantitatively by Fick, who adapted 
equations of thermal conductivity applied earlier by Fourier to diffusion. The definition 
of the law is as follows: the quantity of the dissolved substance (dw) which diffuses at a 
constant temperature through a cross-sectional area (A) within a time (dt), through a 
layer of thickness (dx) which is perpendicular to surface A on the effect of a 
concentration gradient (dC): 
 
                                                                                                                    (1) 
 
 
where D is the diffusion coefficient (the quantity of dissolved substance which diffuses 
through a 1 cm
2
 cross-sectional area per unit time). 
1. impermeable backing layer; 2. drug in adhesive; 3. release liner 










For the characterization of different dosage forms are applied different kinetic models, 
which are based on the equation of Fick.  
The TTS can be grouped in 2 major types respectively the release kinetics of drugs: 
 
- adhesive matrix systems 




3.7.1.  Release kinetics from matrix devices 
 
In dissolved systems, an adhesive matrix system contains drug dissolved at or below the 
saturation solubility of the drug in the adhesive. Diffusion of drug occurs from the 
surface of patch into water or skin. In ideal case, the fraction (F) released from a matrix 










Mt= amount of drug released into a sink at time t 
M∞= amount released on depletion of the device 
D= diffusion coefficient 
L= thickness of matrix film 
n= integer 
This equation (2) is more complex in nature, so for simplicity it can be distinguished an 
















The drug can be found in dispersed-type systems as finely divided particles uniformly 
dispersed in the polymer matrix. Therefore, the initial drug concentration (Ai) is greater 
than the saturation solubility (CS). The drug release kinetics from a dispersed-type 
matrix system is described as follows [82]: 
    
                                                                                                                    (3) 
 
where: 
CS= saturation solubility 
Ai= initial drug concentration 
Once the dispersed drug is exhausted from the matrix, the drug release kinetics 
essentially follows the kinetics of drugs from dissolved systems. 
 
The porous matrix system has continuous macroscopic channels. The release kinetics is 
mainly dependent on the transport of drug through these tortuous channels. The 











The porosity can be determined from the volume fraction of the transdermal device that 
is permeated by solvent. Tortuosity is a measure of the diffusion length, which the 
solute would traverse through the channel in excess of linear path [84, 85]. 



















3.7.2.  Release kinetics from gelled liquid reservoir systems 
 
Reservoir patches contain the drug mainly in solution in appropriate vesicles. The 
viscosity of this solution is increased with an appropriate gelling or thickening agent to 
make the fabrication of the reservoir patches easier. The release kinetics of the drug 
through the gel and the rate-controlling membrane of a liquid reservoir patch follow 




3.7.3. Analysis of the release profiles according to different kinetic 
models 
 
In the in vitro evaluation of patches  are often applied the following models, which are 
more simplified as the ones described above and are often used in the kinetic 
characterization of transdermal devices. 
 
Zero-order model 
The drug release from the dosage form follows a steady-state release running at a 
constant rate [86, 87]: 
 
           Mt/M∞= kt             (5) 
 
where  
Mt= the amount of the drug released at time t,  
M∞= the total amount of the released drug at infinite time, 
k= the zero order rate constant of the drug release. 
 
This model can be applied for drug dissolution from pharmaceutical dosage forms that 
do not disaggregate and release the drug slowly (assuming that area does not change 







The drug activity within the reservoir is assumed to decline exponentially and the 
release rate is proportional to the residual activity: 
 
        Mt/M = 1– exp(–kt)                       (6) 
 
where  
k= first order rate constant of the drug release. 
 
Weibull model 
A general empirical equation described by Weibull was adapted to the dissolution / 
release process. This equation can be successfully applied to almost all kinds of 
dissolution curves and is commonly used in kinetic studies. 
To characterize the dissolution profile of patches the Weibull distribution was applied in 
the following form [88]: 
 
 
      (7) 
 
where 
Mt=the dissolution (%) at time t (min), 
M∞=the dissolution (%) at infinite time, 
t0=the lag-time (min) of the dissolution, 
β=shape parameter of the curve, 



















In the literature overview of the thesis, I summarized the references which are 
connected with the transdermal delivery and their applications in the pharmaceutical 
practice. I gave an overview about transdermal delivery devices, especially focused on 
the matrix type ones. I represented the different polymers which were used to form 
matrices and enable the drug release from the obtained transdermal systems. The kinetic 
aspect of the controlled drug release in transdermal therapeutic systems is also 
presented regarding to their drug depot characteristics.  
The objectives of the experimental part of my thesis were: 
 
 
- to formulate patches containing standard amount of metoprolol tartrate and 
different amounts of polymers, which are official in the European 
Pharmacopoeia, 
 
- to characterize in vitro the metoprolol tartrate release from the prepared 
patches, 
 
- to analyze the relationship between the drug release and the composition of 
the patches regarding to the different polymer ratios, 
 
- to evaluate the applicability and reliability of different kinetic models to 
describe the drug release from the patches, 
 
- to give a relationship between the drug release and the ability of the polymer 
matrix to form secondary structures, 
 
- to evaluate in process the patches with appropriate polymer ratio for the 






5. EXPERIMENTAL PART 
 






Metoprolol tartrate of Ph. Eur. was selected as a highly water-soluble model drug. 
The following excipients were applied for the preformulation examinations and for the 
preparation of the patches: 
 
- Eudragit RL 30 D (USP/NF, JPE, Ph. Eur.; Evonik Röhm GmbH, 
Darmstadt, Germany) 
- Eudragit RS 30 D (USP/NF, JPE, Ph. Eur.; Evonik Röhm GmbH, 
Darmstadt, Germany) 
- Eudragit NE 30 D (USP/NF, JPE, Ph. Eur.; Evonik Röhm GmbH, 
Darmstadt, Germany) 
- Triethylcitrate (Hungaropharma, Budapest, Hungary) 
- Polyethylene glycol (PEG400) (Hungaropharma, Budapest, Hungary) 
- Sucrose stearate S1570 (Mitsubishi Chemical Co., Japan) 
- Sucrose laurate L1695 (Mitsubishi Chemical Co., Japan) 
- Metolose 90 SH 100.000 SR (USP, Ph. Eur.; Shin-Etsu Chemical 
Company, Tokyo, Japan) 
- Metolose SM 4000 (USP, Ph. Eur.; Shin-Etsu Chemical Company, Tokyo, 
Japan)  
 
5.1.1.1. Application of metoprolol tartrate  
 
Metoprolol tartrate is a selective hydrophilic ß-blocking agent for the treatment of mild 
and moderate hypertension and also for long term management of angina pectoris. 
Metoprolol tartrate is 95% absorbed and has a bioavailability of 40- to 50%. In the 





CNS and has moderate lipid solubility. The metabolism of this drug is hepatically 
(primarly by CYP2D6). The metabolization occurs also mainly in the liver. 
Approximately 95% of the drug is excreted renally and less than 5% of the drug is 
excreted unchanged in urine.  
Reduction of exercise induced tachycardia is proportional to the logarithm of the plasma 
concentration over the range of 20–100 μg/L and effects are detected at 50–100 μg/L. 
Peak plasma concentrations are achieved after 2–3 hours. Half life of the molecule is 3 
to 7 hours. The plasma half-life is about 4 hours [89, 90], which makes frequent dosing 
necessary to maintain the therapeutic blood levels of the drug for long-term treatment. 
The n-octanol/water partition coefficient is 0.98 at pH 7.4. Therefore, metoprolol is an 
ideal drug candidate for transdermal drug delivery. The drug has previously been 
investigated for its skin permeation potential with menthol as a penetration enhancer 
[91], as a part of liposomal formulations [8] and also as an active ingredient of 

















5.1.1.2. Application of acrylates 
 
Acrylic polymers have been known for a long time. They have favorable 
biocompatibility, good skin adhesion property and good compatibility with a wide range 
of drugs and excipients. 
Polyacrylates are saturated hydrocarbon polymers (Figure 8). Therefore they are highly 
resistant to oxidation and do not require the addition of stabilizers, the application of 
which could lead to skin irritation. These polymers are inherently tacky, and therefore, 
in general they do not need low molecular weight tackifiers and plasticizers to provide 
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Figure 8 – Chemical structure of acrylic polymers [94] 
 
Poly acrylic esters are produced by copolymerization of acrylic esters, acrylic acid and 
other functional monomers. Commonly used modifying monomers include vinyl 
acetate, methyl acrylate, methyl and ethyl methacrylate, acrylic and methacrylic acid, 
acrylnitrile and certain amine-functional monomers. These modifying monomers can be 
used to change the solubility and / or permeability of the acrylic polymers. Water-
soluble or hydrophilic monomers such as vinylpyrrolidone, 2-hydroxyethyl acrylate and 







5.1.1.3. Application of cellulose ether polymers 
 
Cellulose ethers are derivates of cellulose. They are formed through partial or total 
substitution of the hydroxyl groups in the so called etherification. There are different 
forms of cellulose ethers such as carboxymethylcellulose, methylcellulose, 
ethylcellulose and hydroxymethyl-, hydroxyethyl- and hydroxypropylcellulose, etc. The 
physical and chemical properties of cellulose ethers depend on the way and the grade of 
substitution. Table 1 summarizes the data of the cellulose types which are applied in the 
preparation of patches.  
 
Table 1 – Characteristics of the applied Metolose types [95]  
 
Metolose types   Methoxyl        Hydroxypropoxyl         Viscosity* 
   content (%)  content (%)            (cP) 
SM 4000  27.5-31.5       –        3000-5600  
90 SH 100.000 SR 19.0-24.0  4.0-12.0  75.000-140.000 
 






Methylcellulose is formed from long-chain substituted cellulose in which approximately 
27–32% of the hydroxyl groups are in the form of the methyl ether (Figure 9). The 
different types of methylcellulose have degrees of polymerization in the range 50–1000, 
with molecular weights in the range 10.000–220.000 Da. The degree of substitution of 
methylcellulose is defined as the average number of methoxy (CH3O) groups attached 
to each of the anhydroglucose units along the chain. The degree of substitution also 
affects the physical properties of methylcellulose, such as its solubility and the viscosity 







Figure 9 – Chemical structure of methylcellulose [94] 
 
 
Methylcellulose is widely used in oral and topical pharmaceutical formulations. The 
following application forms can occur in tablet formulations: 
- binding agents (low- or medium-viscosity grades of methylcellulose). 
Methylcellulose is added either as a dry powder or in solution [96], 
- disintegrants (high viscosity grades of methylcellulose) [97], 
- to produce sustained-release preparations, 
- to spray-coat (highly substituted low-viscosity grades of methylcellulose) tablet 
cores to mask unpleasant taste or to modify the release of drug by controlling 
the physical characteristics of the granules [98], 
- to seal tablet cores prior to sugar coating. 
 
 
In liquid formulations the following application fields are involved: 
- emulsify different types of oils (low-viscosity grades of methylcellulose), 
- suspend or thicken orally administered liquids (low-viscosity grades of 
methylcellulose) [99]. Methylcellulose delays the settling of suspensions and 
increases the contact time of drugs, such as antacids, etc. 
In topically applied creams and gels are applied high-viscosity grades of 





high-viscosity grade of methylcelluloses [100]. Methylcellulose types can be also found 
in injectable formulations.  
Therapeutically, methylcellulose is used as a bulk laxative; it has also been used to aid 
appetite control in the management of obesity. Practically insoluble in acetone, 
methanol, chloroform, ethanol (95%), ether, saturated salt solutions, toluene, and hot 
water. It is soluble in glacial acetic acid and in a mixture of equal volumes of ethanol 
and chloroform. In cold water, methylcellulose swells and disperses slowly to form a 




Hypromellose is a partly O-methylated and O-(2-hydroxypropylated) cellulose (Figure 
10). The different types of hypromellose vary in viscosity and extent of substitution. 
Grades may be distinguished by appending a number indicative of the apparent 
viscosity, in mPas, of a 2% w/w aqueous solution at 20°C. 
Molecular weight is approximately 10.000–1.500.000.  
 
where R is H-, CH3- or CH3CH(OH)CH2- 
 
Figure 10 – Chemical structure of hypromellose [94] 
 
These excipients are applied in oral, ophthalmic, nasal, and topical pharmaceutical 
formulations. In tablet formulations hypromellose is primarily used: 
- tablet binder excipient [101],  






- to form matrix for use in extended release tablet formulations [103, 104],  
- to retard the release of drugs from a matrix (at levels of 10-80% w/w), 
- to film-coat tablets (at levels of 2-20% w/w). 
 
Hypromellose is also an ideal candidate as a suspending and thickening agent in topical 
formulations. It is a much better candidate for ophthalmic formulations because of the 
clarity of solutions made with hypromellose compared with the solutions made with 
methylcellulose. It forms fewer undissolved fibers. Therefore at low concentration level 
(0.45–1.0% w/w) hypromellose may be added as a thickening agent for eye drops and 
artificial tear solutions. It is also used commercially in liquid nasal formulations at a 
concentration of 0.1% [105] 
In topical gels and ointments hypromellose can be applied as an emulsifier, suspending 
agent, and stabilizing agent. As a protective colloid it can prevent droplets and particles 
from coalescing or agglomerating. It is also widely used in cosmetics and food products. 
Hypromellose powder is a stable material, although it is hygroscopic after drying. 
Solutions are stable at pH 3–11. A reversible sol–gel transformation upon heating and 
cooling can be observed with hypromellose. The gelation temperature is 50–90°C, 
depending upon the grade and concentration of this material. Viscosity of the solution 
decreases as temperature is increased below the gelation temperature, while beyond the 
gelation temperature viscosity increases as temperature is increased. Aqueous solutions 
of hypromellose are quite enzyme-resistant, thus provides good viscosity stability 
















5.1.2.1. Method for preparation of patches 
 
In the first step, 2/3 part of water was heated to 70 ºC. Metoprolol tartrate, the different 
types of Metolose of various proportions and the different additives were dissolved 
homogeneously in the hot water. The remaining 1/3 part of the water, stored at 5 ºC, was 
added after homogenizing. This mixture was stirred until dissolving of the components 
and afterwards it was cooled. At room temperature (25 ºC) the different acrylic polymer 
solutions were added to the system applying a low stirring rate to avoid forming of air 
bubbles.  
This preparation method enabled that metoprolol tartrate is completely dissolved before 
embedded in the matrix and is fully dispersed in the polymer system in the course of the 
drying process. In the cooling step of the preparation of the patches, there is an increase 
in the viscosity of the solution containing Metolose, which makes more difficult to mix 
it with the polyacrylate solution thoroughly. 
The homogenous mixture was filled into a gum ring of a constant diameter (54 mm). 
Each sample contained 7.5 g of this mixture. The metoprolol tartrate concentration of 
the mixture was 1.11% w/w in each sample. The drying of the samples was performed 
at room temperature for a 3 day period. The further investigations were done after this 3 
day period. First the thickness of patches was checked and in each formulation was 
found similar. 
 
5.1.2.2. Organoleptic examination of different compositions for preparing 
applicable patches 
 
For the determination of the incompatibility between the model drug and the polymer 
matrix forming components I prepared patches and after 3 days of storage in exsiccator 
with organoleptic observation I chose the macroscopically homogeneous candidates for 
further examinations. 
 
5.1.2.3. Viscosity measurements 
 
The prepared gel formulations at room temperature were filled into the cylinder of the 





measurements were done at 25°C. For the evaluation the balance viscosity values of 
each formulation (n=3) were taken. The viscosity – time curves were recorded with the 
following parameters: disc SV2, G= 50 1/min, measurement time was 15 min.  
 
5.1.2.4. Optimization of composition according to the drug liberation 
examinations 
 
This test was performed by Hanson SR8-Plus (Hanson Research, Chatsorth, USA) 
according to Ph. Eur. regulation – Paddle over disk. TTS samples after 3 days of storage 
were placed into a disk apparatus. Then they were immersed into the temperature-
controlled 400 ml acceptor medium (pH = 6.00 buffer solution). The acceptor medium 
was kept at 32 ±1°C and mixed at the rate of 25 rpm with rotating pad. Samples were 
taken at predetermined time points with AutoPlus Maximizer system and an Auto Plus 
MultiFill collector (Hanson Research, Chatsorth, USA). The sample volume was 10 ml, 
which was replaced each time with the equivalent of dissolution medium. The active 
content of the samples was determined with an Auto Plus On-Line UV/VIS 
Autosamples spectrophotometer at 274 nm on the basis of a calibration curve recorded 









5.1.2.5. Analysis of the release profiles according to different kinetic models 
 
The following mathematical models were evaluated considering the drug release 
profiles of the patches. The non-linear parameter estimation of the release models 
applied for matrices was made with the Solver function of the computer package 
Microsoft Excel 5.0. 





5.1.2.6. FT-IR examinations 
 
FT-IR spectra of the cast film patches were obtained using a JASCO FT/IR-4200 
spectrometer in 4000-400 cm
-1 
wavenumber range. 32 scans were performed at a 
resolution of 4 cm
−1
. The system was operated in the transmission mode. Spectra 
Analysis software was applied for the determination of the peak area within the 




5.1.2.7. Non-invasive stability screening of patches with ATR-FTIR 
examinations  
 
The prepared matrices with and without metoprolol tartrate were stored 1 month at 
40±2°C and 75±5% relative humidity in open container. 
The ATR-FTIR spectra of the stored patches with and without metoprolol tartrate 
samples were scanned over wavenumber range of 4000–600 cm
−1
 using Able Jasco FT-
IR 4200 type A spectrometer with ATR Pro470H single reflection ATR accessory. 32 




5.1.2.8. Positron annihilation lifetime spectroscopy (PALS)  
 
Positron annihilation lifetime spectroscopy (PALS) is a unique method since it is 
exceptionally sensitive to the free volume. It is frequently used to determine the size 
distribution of free volume holes in polymers. 
 





the interaction of the free volume holes and the so called ortho-positronium atom. 
When positrons are injected to an amorphous molecular material they form three 
different states in the simplest case. A part of them forms positronium (Ps) atoms with 
the electrons of the material. This exotic atom, which is the bound state of an electron 
and a positron, has two ground states depending on the relative orientation of the spins 
of the constructing particles. The para-Ps, in which the spins are anti-parallel, has a 
very short intrinsic lifetime (125 ps). The usual reactivity of Ps atoms is not very high 
and in most of the cases the two particles bound in para-Ps (the positron and the 
electron) annihilate with each other by the intrinsic lifetime ( 1). The other ground state 
of positronium is the ortho-Ps (o-Ps), in which the spins are parallel. This Ps state has a 
very long lifetime in a vacuum (141 ns) and, even at very low reactivity, it interacts with 
the electrons of the surrounding material considerably. Usually the positron of the 
ortho-Ps does not annihilate with its own electron but rather with an electron of the 
material. This interaction decreases the intrinsic lifetime significantly and usually a 
much shorter lifetime is observed (1-10 ns). Even so, this is the longest lifetime 
component of positron lifetime spectra ( 3). 
The third state of positrons in materials is usually due to positrons not able to form Ps 
atoms. These positrons diffuse almost freely in the material but they should also 
annihilate sooner or later with surrounding electrons, i.e., with the electrons of 
polymeric chains in our case. This provides a medium long lifetime ( 2) that 
characterizes the average electron density of the material. This lifetime component 
usually reflects tiny changes of the electron structure of a material very sensitively. In 
amorphous materials as polymers the size of free volume holes is not uniformly 
distributed. Consequently, the simple assumption on the number and the nature of 
positron states is not necessarily correct. In these materials, instead of one well defined 
o-Ps state, a number of similar states occur depending on the size of the free volume 
around the positronium. So the lifetime spectrum, S(t) is not a simple sum of 
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where i-s are the assumed separate lifetimes, Ai-s are their relative intensities, while the 
function h( ) is the lifetime distribution function which is proportional with the size 
distribution of free volume holes in the material. 
In polymers the formed o-Ps atoms tend to be trapped in free volume holes and, as 
mentioned above, their annihilation is not governed by their intrinsic lifetime but by the 
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where  is the positronium lifetime, R is the radius of the free volume hole, and R is a 
constant. Consequently, on the basis of o-Ps lifetime distributions we gain a detailed 
picture on the size distribution of free volume holes [106, 107].  
The positron source applied for the measurements was made of carrier free 
22
NaCl of 
the activity of 4x10
5
 Bq. The active sodium chloride was sealed between two very thin 
kapton foils. The source was then placed between two pieces of the sample treated 
identically before. Positron lifetime spectra were recorded by a conventional fast-fast 
coincidence system. The system was constructed from standard ORTEC electronic 
units, while the detectors from BaF2 scintillator crystals and XP2020Q photomultipliers.  
The time resolution of the system was about 200 picoseconds. The spectra were 
evaluated into three lifetime components. The two shorter lifetime components (165ps, 
460ps) are mixtures of different positron and positronium states. As they are too 
complicated to interpret physically, they were ignored in the evaluations. The longest 
living positron state is due to ortho-positronium. The lifetime of this positronium state 
is, in the case of polymers, connected with the size of free volume holes [108]. The 









5.2.1. Preformulation examinations 
 
5.2.1.1. Preparation of Eudragit films for further formulation of matrices 
containing metoprolol tartrate 
 
The aim of the preformulation examinations was to create matrix type patches with the 
combination of polyacrylate polymer and different additives to embed the model drug 
(metoprolol tartrate). For this reason there were investigated several types of 
polyacrylate polymer solutions in combination with metoprolol tartrate for 
compatibility. For these examinations I prepared different samples with Eudragit RL 30 
D, Eudragit RS 30 D and Eudragit NE 30 D with different additive such as triethyl-
citrate, PEG400, Sucrose stearate S1570, Sucrose laurate L1695. Acrylates are suitable 
to formulate oral dosage forms which are able to release their content in different parts 
of the GI tract. According to their functional groups they can influence at which pH 
values they swell and get permeable. There are also several types which enable the 
applied drugs to be released with time control under independent pH values [109]. 
There can be found several examples in the literature for the application of Eudragit 
polymers to formulate transdermal matrices: mainly the following two types are 
mentioned as a part of matrix formulations: Eudragit RS and Eudragit RL [110-114]. 
These two types have trimethyl-ammonioethylmethacrylate as functional group which 
enables high permeability and pH independent swelling. The application of Eudragit NE 
30 D (aqueous dispersion of a neutral copolymer based on ethyl acrylate and methyl 
methacrylate) in matrix type patches can be also advantageous, because of its time-
controlled drug release properties [69, 115, 116]. For the formulation of matrices these 3 
types were chosen.  
The aim of the first formulations in the developing of matrices was to obtain structures 
which can be manufactured with film casting method resulting in patches which are 
flexible and applicable on the skin. Eudragit RS and Eudragit RL were applied for 
preparing matrices alone and also with different plasticizers. The summary of 





Table 2 – Patches with different acrylate components and different additives on wet 





RS 30 D 
 
Eudragit 
RL 30 D 
Eudragit 













Polymer content (%w/w) 
1. 30.00 - - - - - - rigid 
2. 28.57 - - - 4.76 - - rigid 
3. 27.27 - - - 9.09 - - rigid 
4. 26.09 - - - 13.04 - - rigid 
5. 25.00 - - - 16.67 - - rigid 
6. 24.00 - - - 20.00 - - rigid 
7. 23.08 - - - 23.08 - - rigid 
8. 22.22 - - - 25.93 - - rigid 
9. 21.43 - - - 28.57 - - rigid 
10. - 30.00 - - - - - rigid 
11. - 28.57 - - 4.76 - - rigid 
12. - 27.27 - - 9.09 - - rigid 
13. - 26.09 - - 13.04 - - rigid 
14. - 25.00 - - 16.67 - - rigid 
15. - 24.00 - - 20.00 - - rigid 
16. - 23.08 - - 23.08 - - rigid 
17. - 22.22 - - 25.93 - - rigid 
18. - 21.43 - - 28.57 - - rigid 
19. 28.57 - - 1.43 - - - rigid 
20. 27.27 - - 2.73 - - - flexible 
21. 26.09 - - 3.91 - - - flexible 
22. 25.00 - - 5.00 - - - flexible 
23. 24.00 - - 6.00 - - - flexible 
24. 23.08 - - 6.92 - - - flexible 
25. 22.22 - - 7.78 - - - flexible 
26. 21.43 - - 8.58 - - - flexible 
27. - 28.57 - 1.43 - - - rigid 
28. - 27.27 - 2.73 - - - flexible 
29. - 26.09 - 3.91 - - - flexible 
30. - 25.00 - 5.00 - - - flexible 
31. - 24.00 - 6.00 - - - flexible 
32. - 23.08 - 6.92 - - - flexible 
33. - 22.22 - 7.78 - - - flexible 
34. - 21.43 - 8.58 - - - flexible 
35. - 29.93 - - - 0.25 - rigid 
36. - 29.85 - - - 0.50 - rigid 
37. 29.93 - - - - 0.25 - rigid 
38. 29.85 - - - - 0.50 - rigid 
39. - 29.93 - - - - 0.25 rigid 
40. - 29.85 - - - - 0.50 rigid 
41. 29.93 - - - - - 0.25 rigid 
42. 29.85 - - - - - 0.50 rigid 






5.2.1.2. Optimization of formulations using different Metolose types  
 
Different matrix type patches were created for the further examinations with Eudragit 
NE 30 D and with different types of Metolose (Table 3) and with different additives. 
Figure 12 illustrates the release profiles of the different samples on wet basis. 
 
Table 3 – Preformulation examinations of different excipients for preparing patches on 
wet basis (% w/w) 
 
Components / Sample number 44 45 46 47 48 
Metoprolol tartrate 1.11 1.11 1.11 1.11 1.11 
Eudragit NE 30 D (polymer content) 6.67 6.67 6.67 6.67 6.67 
Metolose SM 4000 2.00 2.00 2.00 1.60 1.00 
Metolose 90 SH 100.000 SR 0.00 0.00 0.00 0.40 1.00 
Sucrose stearate S1570 0.00 0.80 0.00 0.00 0.00 












5.2.1.3. Viscosity aspects for the preformulations 
 
During the preparation of the patches in the cooling process, there can be observed a big 
increase in the viscosity of the solution containing the different Metolose types and the 
active ingredient. This increase makes more difficult to make a homogenous, totally 
dispersed system in which the active ingredient is also totally dispersed. Figure 13 and 
14 represent the viscosity effect on the solution of the two Metolose types in different 





























0.50%  metoprolol tartrate
 
Figure 14 – Viscosity profile of the solution containing Metolose 90 SH 100.000 SR 
(n=3, RSD<5%) 
 
5.2.2. Results of the analysis of the TTS systems 
 
5.2.2.1. Drug liberation examinations 
 
To analyze the effect of the Metolose components of the matrix type patches on drug 
liberation there were investigated the following formulations included in Table 4. The 
composition of each patch is represented on wet and on dry basis (w/d, % w/w). Table 5 
summarizes the kinetic data of the different formulations evaluated by using the Weibull 
method. On the base of the release profile, zero-order model and first-order model 
cannot be applied for the evaluation of the kinetic properties of each patch. The 
calculations assume that the whole drug amount will be totally released from the 
patches into the acceptor medium. Figure 15 illustrates the drug release profile of the 
















Table 4 – Patches with different Metolose contents on wet and on dry basis (% w/w) 
 
Components / Sample number 49 50 51 52 53 54 
Metoprolol tartrate 1.11/11.08 1.11/11.02 1.11/11.05 1.11/10.82 1.11/10.81 1.11/10.90 
Eudragit NE 30 D 
(polymer content) 6.67/66.57 6.67/66.21 6.67/66.37 6.67/65.02 6.67/64.96 6.67/65.50 
Metolose SM 4000 2.00/19.96 1.80/17.87 1.60/15.92 1.40/13.65 1.20/11.69 1.00/9.82 
Metolose 90 SH 100.000 SR 0.00/0.00 0.20/1.99 0.40/3.98 0.60/5.85 0.80/7.79 1.00/9.82 











number τ63.2 (min) t0 β R
2
 
49 4087.58 0.00 0.51 0.995 
50 905.23 0.00 0.58 0.994 
51 189.53 0.00 0.42 0.966 
52 178.61 0.00 0.46 0.973 
53 150.17 0.00 0.59 0.993 









Figure 15 – Drug release profile of patches containing different proportions of                                                     
polymers (n=3, RSD<5%) 
 
5.2.2.2. Storage of patches  
 
Metoprolol tartrate can be stored as a free drug for a long period of time without any 
chemical and physical degradation. Similar results have been found in matrix type 
matrices. These matrices contained metoprolol tartrate, polyacrylic polymer, polyvinyl 
alcohol [117, 118].  
Each formulation was stored under stress conditions at 40±2°C and 75±5% relative 
humidity in open container. ATR-FTIR spectroscopy was applied to detect the stability 
changes of intact patches in the course of storage. Figure 16 illustrates the ATR-FTIR 
spectra of one combination of patches (Sample 53). After 1 month of storage, neither in 
the spectra of patches containing metoprolol tartrate nor in those without the active 
agent any other peak could be identified. Figure 17 represents the spectra of Sample 52 







Figure 16 – Comparison of the ATR-FTIR spectra of the patches (Sample 53) 




Figure 17 – Comparison of the ATR-FTIR spectra of the patches (Sample 52) 







5.2.2.3. FT-IR examinations  
 
I investigated how the drug release and FT-IR characteristics of Metolose patches were 
influenced by the changes of Metolose SM 4000 (methylcellulose) and Metolose 90 SH 
100.000 SR (hypromellose) proportions. FT-IR spectroscopy measurements were 
performed in parallel with the metoprolol tartrate release study to track the effect of the 
composition on the drug release.  
The characteristic FT-IR peaks of metoprolol tartrate are summarized in Table 6. The 
presence of metoprolol tartrate could be identified according to its characteristic peaks 


































Table 6 – Vibrational band assignment for metoprolol tartrate [119] 
 
      Frequency (cm
-1
)    Vibrational band assignment 
  FTIR          
 
3459 (w)    N-H stretching 
3033 (w)    O-H stretching 
2983 (m)    N-H/C-H symmetric stretching 
2938 (w)    C-H stretching 
2875 (m)    C-H stretching 
2813 (w)    C-H stretching of CH2 group 
2745 (vw)    N-H symmetric stretching 
2572 (vw)    N-H stretching 
2552 (w)    N-H stretching 
2452 (w)    O-H stretching 
1590 (s)    CO2 antisymmetric stretching 
1514 (s)    CO2 asymmetric stretching 
1460 (m)    O-H/C-H deformation 
1400 (m)    Aromatic ring stretching 
1358 (m)    CH3 deformation 
1300 (m)    O-H deformation 
1250 (s)    O-H deformation 
1235 (m)    C-N deformation 
1181 (m)    C-O stretching 
1164 (m)    C-O antisymmetric stretching 
1112 (s)    C-O asymmetric stretching 
1074 (w)    Aromatic ring stretching 
1054 (m)    C-O stretching 
1014 (m)    C-O deformation 
967   (m)    O-H deformation 
935   (m)    out of plane O-H vibration of  
carbonyl group 
821   (s)     out of plane O-H vibration of  
carbonyl group 
780   (w)    Liberation of H2O 
686   (m)     out of plane O-H vibration of  
alcohol  
605   (m)     out of plane O-H vibration of  
alcohol 
542   (m)    O-H torsional vibration 
508   (m)    CO2 deformation  
                       
 








Figure 18 - FT-IR spectra of different patches with metoprolol tartrate 
 
Sample 50 - Metolose SM 4000 concentration 1.80% (AUC=5919.2)-1 a, b 
Sample 51 - Metolose SM 4000 concentration 1.60% (AUC=6783.9)-2 a, b 
Sample 52 - Metolose SM 4000 concentration 1.40% (AUC=10034.2)-3 a, b 
Sample 53 - Metolose SM 4000 concentration 1.20% (AUC=12333.7)-4 a, b 
Sample 54 - Metolose SM 4000 concentration 1,00% (AUC=18167.2)-5 a, b 
 
Spectra with “a” are the spectra of blank patches, while spectra with “b” are the 






5.2.2.4. Positron annihilation lifetime spectroscopy (PALS)  
 
Figure 19 represents the o-Ps lifetime distribution in 3 samples. Compositions see in 
Table 4.  
 
 























5.3.1. Formulation considerations of applicable patches 
 
According to the results of the preformulation examinations (Table 2) the application of 
triethylcitrate with Eudragit RS 30 D and Eudragit RL 30 D in appropriate amount 
resulted in flexible matrices. These formulations were then prepared with metoprolol 
tartrate (applied amount of drug was: 1.11 w/w % on wet basis) to investigate the drug 
release profile of patches (Sample 20 and 28). Drug release measurements showed that 
the drug could not liberate from these two compositions.  
For further examinations we have chosen Eudragit NE 30 D because this polyacrylate 
polymer does not require any additional plasticizer or the application of lower amount 
of plasticizer can ensure similar physicochemical characteristics like in the case of 
Eudragit RS 30 D and RL 30 D. Sample 43 was then prepared with metoprolol tartrate 
(applied amount of drug was: 1.11 w/w % on wet basis) to examine the drug release 
profile of patches. The measurements showed that no drug could liberate from this 
composition. 
Eudragit NE was afterwards combined in different proportions with Metolose SM 4000.  
During the optimization of formulations (Table 3) using different Metolose types the 
different compositions show different release profiles (Figure 12). It can be observed 
that the combination of Eudragit NE 30 D and Metolose SM 4000 leads to very low 
drug release, so this formulation needs to be modified with other components. In the 
case of application of Sucrose stearate S1570, there is a great increase of released drug, 
however, in the 1. hour already 67.7% of the drug amount is released. The application of 
Sucrose laurate L1695 leads to the increase of the released drug, but only 57.7% of the 
whole drug amount is released in the 6. hour of examination. The application of 
plasticizers resulted in a great increase of released drug without any possibility for the 
modification in the kinetics of the drug release. In the case of Metolose 90 SH 100.000 
SR it can be observed that the released drug amount can be modified with the different 
amounts of Metolose 90 SH 100.000 SR. According to the results of the drug liberation, 





SH 100.000 SR can be used for preparing matrix type patches containing metoprolol 
tartrate. 
Viscosity data (Figure 13 and Figure 14) showed, that the application of metoprolol 
tartrate in smaller concentrations has effect on the viscosity in the case of both cellulose 
polymers. It leads at low concentration level of Metolose 90 SH 100.000 SR to small 
increase of viscosity and at low concentration level of Metolose SM 4000 it tends to 
lower the viscosity of the solution. The application level of Metolose 90 SH 100.000 SR 
increases much more intensively the viscosity of the solution, which results in a lower 
application level of this polymer for preparing the patches. On the grounds of the 
viscosity measurements and the empirical experiences, Metolose 90 SH 100.000 SR can 
be applied up to 1.0% w/w, Metolose SM 4000 can be used up to 2.0% w/w for the 
preparation of the patches. 
 
5.3.2. Kinetic considerations of the release profiles 
 
As discussed above, the applied polymers alone were not able to form adhesive and 
flexible patches of controlled drug release, thus a mixture of Eudragit NE 30 D and two 
types of Metoloses were used to obtain the required characteristics. Compositions see in 
Table 4. The water insoluble, pH independent, water swellable, and water permeable 
Eudragit NE 30 D enables the barrier function of the homogeneous polymer composite. 
Since the concentration of the Eudragit NE 30 D was kept constant in each patch 
(6.67% w/w on wet basis), the drug release profile was controlled by the various 
proportions of water-soluble Metolose SM 4000 and Metolose 90 SH 100.000 SR. No 
lag-time (t0 = 0) values were detected (Figure 15).  
The extending ratio of Metolose 90 SH 100.000 SR enables higher extent of metoprolol 
tartrate release, which indicates that the presence of the hydroxypropoxyl groups in the 
polymer matrix facilitates and controls the drug release. Table 5 shows, that the 
increased ratio of the hydroxypropoxyl groups had no significant effect on the value of 
the shape parameter (β). Since the β values were within 0.42 and 0.59 in the case of 
each patch, the metoprolol tartrate release followed Fickian diffusion. Hydroxyl groups 
are able to form H-bonds with the water while methoxyl groups are not. This explains 





Metolose SM 4000 in the patches, the less the interaction between the water and the 
polymer is. The formation of H-bonds, consequently the water penetration through the 
polymeric patch is more supported with the application of Metolose 90 SH 100.000 SR 
thus increasing the extent and rate of metoprolol tartrate release from the patches. The 
initial slower release refers to the formation of H-bonds due to the swelling process. 
 
5.3.3. Non-invasive stability screening of patches 
 
Figure 16 illustrates the ATR-FTIR spectra of one combination of patches (Sample 53). 
These spectra were made after 1 month of storage. The presence of metoprolol tartrate 
can be identified primarily with the characteristic peak at 1507 cm
-1
 which could refer 
to the CO2 asymmetric stretching in the molecule. This peak can be identified in all 
samples containing the drug; other peaks interfere with the functional groups of the 
polymer matrix and cannot clearly characterize the functional groups of metoprolol 
tartrate. The most characteristic peak of the patch can be found at 1726 cm
-1
. This peak 
can be also identified in each formulation. After 1 month of storage, neither in the 
spectra of patches containing metoprolol tartrate nor in those without the active agent 
any other peak could be identified. Figure 17 represents the spectra of Sample 52 
without storage and with one month of storage. There can be observed any other peak in 
both spectra. The results enable quick non-destructive stability screening of patches. 
According to these results the samples can be found stable during the period of 
observation, which is in good compliance with the results found in the literature 
background. 
 
5.3.4. Relationship between FT-IR spectra and kinetic data of patches 
 
The characteristic FT-IR peaks of metoprolol tartrate are summarized in Table 6. The 
presence of metoprolol tartrate could be identified according to its characteristic peaks 
in those spectra of patches containing the drug.  
Figure 18 illustrates the FT-IR spectra of blank patches and of that containing 
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presence of metoprolol tartrate, which refer to the carbonyl group of methacrylate ester 









 wavenumbers in each blank patch, which could be attributed to the ester 
groups derived from Metolose SM 4000 and Metolose 90 SH 100.000 SR. These peaks 
were disappeared in the presence of metoprolol tartrate. Only one new peak appeared at 
2196 cm
-1
 referring to the aromatic ring of metoprolol tartrate.  
A broad hydroxyl absorption band was found at 3087 cm
-1
 indicating the presence of 
hypromellose. The signs of the OH bands will be much more intensive with the growing 
ratio of hypromellose. The latter was dominant in the empty patches. In the presence of 
metoprolol tartrate the specific absorption band disappeared. The possible explanation 
for this phenomenon could be the interaction between the polymer and metoprolol 
tartrate forming homogenous polymeric composite patches in which metoprolol tartrate 
is entrapped. 
The increase of the transmission values of the characteristic peaks along with the 
Metolose 90 SH 100.000 SR content indicates the microstructural changes of the 
patches via H-bridges with the OH groups of Metolose 90 SH 100.000 SR. Since no 
extraneous peaks were found, the spectra are masking-like and feasible to make 
quantitative analysis due to their positions in the analytical wavenumber range. This 
non-invasive quantitative analysis of patches is based on the determination of the AUC 
values measured within the characteristic wavenumber range.  
Linear relationship was found with good correlation (R= 0.9380) between the area 
under the peak values of the FT-IR curves of Metolose containing patches measured 
within the wavenumber range of 1757.7-2811.8 cm
-1
 and the log τ63.2 values (y) of 
metoprolol tartrate release [120]. 
Figure 20 illustrates the correlation between the peak area and the log τ63.2 values of 







On the basis of our results, the application of FT-IR measurements can be recommended 
as a useful non-destructive means during the in-process control of patches. 
 
5.3.5. Aspects of the positron annihilation lifetime spectroscopy 
(PALS) results 
 
PALS spectroscopy data (Figure 19) showed that the o-Ps distributions are shifted 
towards higher lifetimes in patches, which contain greater amount of Metolose 90 SH 
100.000 SR. However, there is no significant difference between the free volume sizes 
of the different compositions. The microscopic and macroscopic porosity in the 
different patches increased with the increased amount of Metolose 90 SH 100.000 SR, 
which leads to increased permeability, thus resulting in faster initial rate and higher 
extent of drug release [121, 122].  
Figure 21 represents the effect of Metolose SM 4000 relative concentrations on the 
amount of metoprolol tartrate released at the 6. hour. Along with the increase of the 
hydroxypropoxy substitution of patches (Metolose 90 SH 100.000 SR), the extent of 
drug release also increases. The Metolose structure containing hydroxypropoxyl groups 
enables the formation of H-bonds which initiates the water penetration through the 
Figure 20 - Correlation between the peak area measured within the wavenumber range  














patches. The expanded swelling increases the size of free volume holes in the film and 
that, consequently, increases the rate and extent of drug release. As it is obvious from 




Figure 21 - Metoprolol tartrate released (% w/w) at the 6. hour as a function of the 
Metolose SM 4000 relative concentration 
 
 
Figure 22 – Ortho-positronium lifetime values of metoprolol tartrate patches as a 





The released amount of metoprolol tartrate at the 6. hour (% w/w) and ortho-
positronium lifetime ( , ps) values could be described with the following polynomial 
equation as a function of the relative concentration of Metolose SM 4000 (% w/w) in 








where a, b, c are constants. The fitted polynomial curves are shown in both Figure 21 
and 22, respectively. 
 
The constants of the polynomial curve were the following in the case of the released 
metoprolol tartrate vs. Metolose SM 4000: 
 
a = -0.00296 
b = 3.3729 
c = 18.295 
R
2
 = 0.9857 
 
In the case of the ortho-positronium lifetime values vs. Metolose SM 4000, the 
constants were the following: 
 
  a= -0.00061 
b = 0.7936  





The effect of the relative concentration of the Metolose SM 4000 in the patches on the 
free volume of the polymeric matrix and on the released metoprolol tartrate at the 6. 
hour can be characterized by a polynomial relationship with good correlation. This 
relationship helps to design therapeutic systems of predicted drug release. 
Although positronium lifetime data do not indicate a dramatic free volume change, their 





slightly different structure for films containing metoprolol tartrate depending on their 
Metolose SM 4000 and Metolose 90 SH 100.000 SR ratio. To clear this problem, the 
same films without metoprolol tartrate were also studied. Figure 23 represents the o-Ps 
lifetime values of patches as a function of the Metolose SM 4000 relative concentration. 
 
Figure 23 – Ortho-positronium lifetime values of patches as a function of the Metolose 
SM 4000 relative concentration 
 
In this case, all of the films were identical from the viewpoint of positron lifetime 
spectroscopy. All produced the same lifetime of 2010 ps within the statistical error, i.e., 
all of the films had the same free volume size. This indicates that Metolose SM 4000 
and Metolose 90 SH 100.000 SR are interchangeable and have a very similar structure. 
However, the drug encapsulated in them might react differently for the two variants of 
Metolose. In the case of metoprolol tartrate as a drug, Metolose 90 SH 100.000 SR 










New scientific results of the research work: 
 
 
- Eudragit and Metolose based patches containing metoprolol tartrate were created 
with different ratios of the applied polymers to evaluate the drug liberation from the 
different compositions. 
 
- As a result of the pre-formulation work, I determined which polymers from the 
different types of Eudragit and Metolose enable the formation of TTS patches 
containing metoprolol tartrate. The combination of Eudragit NE 30 D and different 
Metolose polymers resulted in novel composition which enabled the formation of 
TTS patches.  
 
- The supramolecular structural elements, connected via H-bonds, strongly influenced 
the drug release from the patches. The changes of the supramolecular structure were 
sensitively tracked with positron annihilation lifetime spectroscopy. The latter 
enabled the visualization of the free volume changes as a function of the polymer 
composition. 
 
- The different ratio of Metolose SM 4000 and Metolose 90 SH 100.000 SR could 
sensitively control the release extent and kinetics of metoprolol tartrate from the 
patches. 
 
- Eudragit NE 30 D enables the barrier function of the polymer composite, while the 
drug release profile was controlled by the various proportions of water-soluble 
Metolose SM 4000 and Metolose 90 SH 100.000 SR.  
 
- The effect of the relative concentration of the Metolose SM 4000 in the patches on 
the free volume of the polymeric matrix and on the released metoprolol tartrate after 





- FT-IR spectroscopy was successfully applied as a quick non-destructive method to 
monitor the stability of intact patches in the course of storage.  
 
- Linear relationship was found with good correlation between the area under the peak 
measured within the characteristic wavenumber range of the FT-IR curves of 
Metolose containing patches and the log τ63.2 values of metoprolol tartrate release. 
The application of FT-IR method enables the fast non-invasive in process control of 







Metoprolol tartrate is a widely used drug as a beta-blocking agent. The oral 
administration of this drug leads to intensive first-pass metabolism, it has a short 
biological half-life and has a bioavailability of 40- to 50%. Among these it has an 
appropriate skin penetration potential. Due to these characteristics it needs to be 
frequently dosed and indicates the application of this drug via transdermal route.  
These long-acting sustained and controlled release transdermal preparations are able to 
ensure systemic effect with predetermined time with steady-state delivery rate. They 
enhance the patient compliance, which is also an important factor of their application. 
The purpose of my thesis was to prepare and evaluate matrix type patches containing 
metoprolol tartrate with different polymer compositions. For this purpose an acrylic 
polymer (Eudragit NE 30 D) and two types of modified cellulose (Metolose SM 4000 
and Metolose 90 SH 100.000 SR) were chosen. The patches were prepared with casting 
method, which enables a fully homogenized embedding of metoprolol tartrate in the 
different polymer matrices. The viscosity, the drug release parameters, the FT-IR spectra 
and the positron annihilation lifetime of the samples were analyzed. The drug release 
from the patches was tested by the rotating paddle method and the drug release data 
were analyzed assuming Weibull kinetic model. The hydrophilic behavior of the 
cellulose polymers and their ratio in the patches can affect the kinetic and the total 
amount of released drug from the samples. The free volume size changes referred to the 
microstructural changes of patches depending on the polymer composition, thus the 
changes in the drug release profile could be confirmed by the o-positronium lifetime 
changes. The correlation between the FT-IR transmittance characteristics of the patches 
and the kinetic parameter values of the metoprolol tartrate release (τ63.2) of patches 
containing Metolose polymers may enable FT-IR measurements as a useful non-














A metoprolol-tartarát széles körben alkalmazott ß-blokkoló hatóanyag, amely adagolása 
során intenzív first pass metabolizmuson megy keresztül. A farmakon biológiai felezési 
ideje viszonylag rövid, biohasznosíthatósága 40- és 50% között mozog. Mindezen 
tulajdonságok mellett megfelelő bőr-penetrációs képességgel rendelkezik. Fentiek 
alapján elmondható, hogy a metoprolol-tartarát terápiás hatásának eléréséhez a 
farmakon gyakori adagolása vagy retard készítmény alkalmazása szükséges, amely 
indokolttá teszi transzdermális készítmény formulálását. 
A kontrollált hatóanyag-felszabadulást hosszú ideig biztosító transzdermális 
készítmények alkalmasak szisztémás hatás kifejtésére előre meghatározott ideig 
konstans hatóanyag-leadási sebesség mellett. Mindezeken felül alkalmazásuk egyik 
fontos pozitív tulajdonsága, hogy növelik a betegek terápiás együttműködő-képességét.  
Értekezésem célja különböző polimerekből álló, metoprolol-tartarát tartalmú tapaszok 
előállítása és vizsgálata volt. A mátrix előállításához Eudragit NE 30 D és két, 
módosított cellulózszármazék (Metolose SM 4000 és Metolose 90 SH 100.000 SR) 
került felhasználásra. A tapaszokat oldatokból öntéses módszerrel állítottam elő. Az 
oldószer elpárologtatása után a különböző polimer mátrixok a metoprolol-tartarátot 
teljesen homogén eloszlásban tartalmazták. A tapaszok előállítása során kialakuló 
reológiai viszonyokat, a hatóanyag-felszabadulás profilját és kinetikai paramétereit 
elemeztem. A minták mikro- és makroszerkezetének összehasonlítására FT-IR 
spektroszkópiai és pozitron annihilációs élettartam spektroszkópiai vizsgálatokat 
végeztem. A minták in vitro hatóanyag-felszabadulását forgólapátos módszerrel 
vizsgáltam, a hatóanyag-felszabadulás kinetikáját pedig Weibull matematikai modell 
segítségével jellemeztem. A cellulóz polimerek hidrofilitása, illetve azok aránya a 
mátrixokban befolyásolta a hatóanyag-felszabadulás mennyiségét és kinetikáját. A 
pozitron élettartam-eloszlás görbék jól szemléltetik a szabadtérfogat változását a 
különböző polimer arányok függvényében, amely a mikroszerkezet-változást 
alátámasztja, és a hatóanyag-felszabadulás polimer-szerkezettől függő profiljának 
magyarázatát adja. A tapaszokat jellemző FT-IR transzmittancia értékek, illetve a 
metoprolol-tartarát felszabadulását jellemző kinetikai paraméter (τ63.2) értékek között 
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